Loading...

SKYE SKYE BIOSCIENCE INC Operational Disruptions 8-K Filing

SKY

SKY

SKYE BIOSCIENCE INC

(SKYE)

2025 8-K

Nasdaq Compliance Notice

Correction Notice

Stock Options Repriced

Nasdaq Compliance Alert

Financial Results Report

CFO Departure Announced

Study Results Update

Collaboration Agreement

Corporate Update

Clinical Trial Results

Financial Statements

Financial Statements

Financial Results

Equity Incentive Update

Financial Results

Management Changes

Incentive Plan Update

Director Appointment and Re...

Clinical Trial Discontinuation

Pro Forma Balance Sheet

Securities Purchase Agreement

Director Appointment and Re...

Securities Purchase Agreement

Agreement, Sale, Termination

Amendment to Articles of In...

Amendment to Incentive Plan

Merger of Equals

Agreement with Emerald Heal...

Resignation and Appointment...

Acquisition of Verd lite Sc...

Stock Purchase Agreement Am...

Amendment and Appointment

External Links:

On October 6, 2025, Skye Bioscience, Inc. released topline data from its Phase 2a clinical trial on Nimacimab, and will host a conference call to discuss the results at 8:00 a.m. E.T. that same day.

AI Assistant

SKYE BIOSCIENCE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.